PYRIDON-A2R-ANTAGONISTEN

European patent · EP3829581 · In force

Register entry

Publication number
EP3829581
Application number
EP19841391
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jul 26, 2019
Published
Jun 9, 2021
Granted
Apr 3, 2024
Protection ends at the latest
Jul 25, 2039
Next annual fee due
Jul 31, 2026
IPC classes
A61K 31/4439 (2006.01)
C07D 401/14 (2006.01)
A61K 31/517 (2006.01)
A61K 31/519 (2006.01)
A61P 35/00 (2006.01)
Priority
US 201862711273 P 27.07.2018
PCT application
PCT/US2019/043608 26.07.2019
PCT publication
WO2020/023846 30.01.2020
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 1, 2025

    Change

    Published in Swissreg on 01.08.2025

  2. Feb 12, 2025

    Change

    Published in Swissreg on 12.02.2025

  3. Aug 1, 2024

    Change

    Published in Swissreg on 01.08.2024

  4. Apr 16, 2024

    Agent entered

    Representative
    MICHELI & CIE SA, 122, rue de Genève,, CP 61, 1226 Thônex

    Published in Swissreg on 16.04.2024

  5. Apr 3, 2024

    Granted

    Published in Swissreg on 03.04.2024

Parties

Holder

Arcus Biosciences, Inc.

3928 Point Eden Way, Hayward, CA 94545, US

Agent

MICHELI & CIE SA

122, rue de Genève, CP 61, 1226 Thônex

Inventor

POWERS, Jay Patrick

Pacifica, California 94044, US

LELETI, Manmohan Reddy

Dublin, California 94568, US

MILES, Dillon Harding

Berkeley, California 94074, US

MANDAL, Debashis

Fremont, California 94536, US

ROSEN, Brandon Reid

San Mateo, California 94403, US

SHARIF, Ehesan Ul

Menlo Park, California 94025, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.